💼InvestingEvaluating Amgen and Vertex Pharmaceuticals reveals two distinct strategies in the healthcare sector, balancing Amgen's diversified portfolio and steady revenue against V…
💳Personal FinanceEnergous Corporation shares dropped 11.27% after posting third-quarter financial results, though leadership highlighted sequential revenue increases and expanding gross m…
🌍World BusinessBavarian Nordic A/S released its third-quarter financial results for the nine-month period ending September 30, 2026, highlighting strong business performance during the …
🌍World BusinessCellectis S.A. executives discussed the company's third-quarter 2026 financial standing and business updates during a conference call on November 13, 2026.
🏛️EconomyZai Lab shares dropped 6.84% to $24.26 on Friday following preliminary Phase 1 data for its experimental eczema treatment, ZL-1503, which showed strong biomarker inhibiti…
🌍World BusinessZai Lab shared initial Phase 1 findings for its atopic dermatitis drug candidate, ZL-1503, highlighting safety and target engagement in healthy volunteers.
📈MarketsVir Biotechnology shares dropped 16.58% in premarket trading on Friday after the clinical-stage biopharmaceutical firm priced a $150 million public stock offering at $10 …
🧠AI AnalysisCytomX Therapeutics is nearing a pivotal data readout for its antibody-drug conjugate Varseta-M in colorectal cancer, setting the stage for a major test of its clinical p…
🧠AI AnalysisViking Therapeutics is advancing multiple late-stage trials for its flagship drug candidate, VK2735, with critical readouts anticipated between 2027 and 2028 that could h…
🧠AI AnalysisAgricultural gene-editing firm Cibus is streamlining operations and prioritizing near-term commercial programs to reduce cash usage following its Q3 2026 update.
🧠AI AnalysisFractyl Health is eliminating nearly half of its workforce and stopping gene therapy research to extend its operational funding. The corporate restructuring follows encou…
🏢CompaniesMinerva Neurosciences executives and medical experts recently gathered to discuss the clinical potential of roluperidone in treating the negative symptoms of schizophreni…
🏢CompaniesTalphera, Inc. held its third quarter 2026 earnings conference call on November 12, 2026, to discuss financial performance and corporate updates.
🧠AI AnalysisCodexis executives outlined their operational progress, financial guidance, and upcoming milestones during the third-quarter 2026 earnings conference call on November 12.
🧠AI AnalysisRelmada Therapeutics reviewed its financial results and corporate progress for the third quarter of 2026 during an earnings conference call led by CEO Sergio Traversa and…
🧠AI AnalysisBelite Bio executives reviewed the company's regulatory advancements and financial performance during their third quarter 2026 earnings conference call on November 12, 20…
🧠AI AnalysisBioCardia executives hosted their third-quarter 2026 earnings call on November 12, outlining the company's financial status and ongoing operational developments for every…
🏢CompaniesOlema Pharmaceuticals CEO discussed the company's upcoming Phase III data readouts and clinical trial momentum at a recent healthcare conference.
🧠AI AnalysisCuris, Inc. hosted its third-quarter 2026 corporate update, reporting steady advancement in its lead primary central nervous system lymphoma program within the TakeAim Ly…
🏛️EconomyModerna shares fell up to 6% in early trading before recovering to a 2% loss following an analyst day event that outlined 2026 financial projections but raised concerns a…
🏢CompaniesAcurx Pharmaceuticals released its third quarter 2026 financial results and corporate updates during an earnings call on November 12, 2026.
Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.